Want to see IL:BLRX full AI Analyst Report?
Total Valuation
Bioline Rx has a market cap or net worth of ₪41.82M. The enterprise value is 33.16.
Market Cap₪41.82M
Enterprise Value33.16
Share Statistics
Bioline Rx has 2,986,929,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,986,929,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bioline Rx’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -33.24%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.03
Return on Invested Capital (ROIC)-33.24%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee58.06K
Profits Per Employee-92.09K
Employee Count22
Asset Turnover0.03
Inventory Turnover0.38
Valuation Ratios
The current PE Ratio of Bioline Rx is ―. Bioline Rx’s PEG ratio is 0.11.
PE Ratio―
PS Ratio9.69
PB Ratio0.68
Price to Fair Value0.68
Price to FCF-1.41
Price to Operating Cash Flow-1.03
PEG Ratio0.11
Income Statement
In the last 12 months, Bioline Rx had revenue of 1.28M and earned -1.27M in profits. Earnings per share was >-0.01.
Revenue1.28M
Gross Profit462.21K
Operating Income-11.14M
Pretax Income-2.19M
Net Income-1.27M
EBITDA-10.57M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -10.94M and capital expenditures 7.16M, giving a free cash flow of -10.97M billion.
Operating Cash Flow-10.94M
Free Cash Flow-10.97M
Free Cash Flow per Share>-0.01
Dividends & Yields
Bioline Rx pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change-43.48%
50-Day Moving Average1.43
200-Day Moving Average1.48
Relative Strength Index (RSI)40.81
Average Volume (3m)3.69M
Important Dates
Bioline Rx upcoming earnings date is Nov 18, 2026, Before Open (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Bioline Rx as a current ratio of 1.95, with Debt / Equity ratio of 58.06%
Current Ratio1.95
Quick Ratio1.78
Debt to Market Cap0.72
Net Debt to EBITDA-0.65
Interest Coverage Ratio-8.04
Taxes
In the past 12 months, Bioline Rx has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bioline Rx EV to EBITDA ratio is -1.82, with an EV/FCF ratio of -2.20.
EV to Sales15.09
EV to EBITDA-1.82
EV to Free Cash Flow-2.20
EV to Operating Cash Flow-2.21
Balance Sheet
Bioline Rx has ₪12.99M in cash and marketable securities with ₪7.94M in debt, giving a net cash position of ₪5.05M billion.
Cash & Marketable Securities₪12.99M
Total Debt₪7.94M
Net Cash₪5.05M
Net Cash Per Share<₪0.01
Tangible Book Value Per Share<₪0.01
Margins
Gross margin is 69.98%, with operating margin of -871.78%, and net profit margin of -99.58%.
Gross Margin69.98%
Operating Margin-871.78%
Pretax Margin-171.69%
Net Profit Margin-99.58%
EBITDA Margin-827.46%
EBIT Margin-871.78%
Analyst Forecast
The average price target for Bioline Rx is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-93.07%
EPS Growth Forecast62.25%